Gland Pharma Ltd Analyst Rating
based on 12 analysts
41.67%
Buy
8.33%
Hold
50.00%
Sell
Based on 12 analysts offering long term price targets for Gland Pharma Ltd. An average target of ₹1813.25
Source: S&P Global Market Intelligence
Gland Pharma Ltd Share analysis
Gland Pharma Ltd price forecast by 12 analysts
Upside of2.01%
High
₹3120
Target
₹1813.25
Low
₹1214
Gland Pharma Ltd target price ₹1813.25, a slight upside of 2.01% compared to current price of ₹1772.3. According to 12 analysts rating.
Excluding Excise Duty and Other Income, represents Net Revenue
Gland Pharma Ltd revenue growth forecast
Expected growth rate Q1, FY2026:21.72%
Forecast
Actual
Including amortisation and stock based compensations
Gland Pharma Ltd EPS growth forecast
EPS estimate Q1, FY2026:39.68%
Forecast
Actual
Source: S&P Global Market Intelligence
Gland Pharma Ltd Performance
Day's Low
Day's High
₹1,765Day's Price Range₹1,794.852 Week's Low
52 Week's High
₹1,585.752-Week Price Range₹2,220.95
| Returns % | |
| 1 Month Return | -0.53 % |
| 3 Month Return | -3.72 % |
| 1 Year Return | -1.71 % |
| Market Stats | |
| Previous Close | ₹1,777.60 |
| Open | ₹1,790.00 |
| Volume | 1.01L |
| Upper Circuit | - |
| Lower Circuit | - |
| Market Cap | ₹29,060.56Cr |
Gland Pharma Ltd Key Statistics
| P/E Ratio | 42.33 |
| PEG Ratio | -96.21 |
| Market Cap | ₹29,060.56 Cr |
| P/B Ratio | 3.37 |
| EPS | 46.9 |
| Dividend Yield | 1.09 |
| Sector | Pharmaceuticals |
| ROE | 12.31 |
Gland Pharma Ltd Peer Comparison
Company | Analyst View | Market Cap | 5 Year CAGR | Debt to Asset Ratio | Net Profit | Yearly Revenue |
|---|---|---|---|---|---|---|
| HOLD | ₹29,060.56 Cr | -0.46% | 0.50 | ₹772 Cr | ₹5,664 Cr | |
| HOLD | ₹1,55,292.48 Cr | 44.39% | 0.50 | ₹1,600 Cr | ₹7,845 Cr | |
| BUY | ₹1,14,453.72 Cr | 54.31% | 0.67 | ₹1,656 Cr | ₹10,727 Cr | |
| HOLD | ₹41,786.88 Cr | 4.53% | 0.58 | ₹1,297 Cr | ₹14,755 Cr | |
| BUY | ₹1,18,913.09 Cr | 44.4% | 0.50 | ₹4,155 Cr | ₹25,774 Cr |
Gland Pharma Ltd Mutual Fund Holdings
About Gland Pharma Ltd
Gland Pharma's operations include the development, manufacture, and marketing of a wide range of injectable drugs and active pharmaceutical ingredients. The company's product portfolio includes antibiotics, anti-emetics, anti-diabetics, anti-epileptics, and other therapeutic categories. Its top products include cephalosporins, penicillins, and other injectable antibiotics.
Gland Pharma is well known for its popular brands, such as Cephalosporin, Penicillin, and Amikacin. These brands have been widely used in hospitals and clinics across India, as well as in other countries. In addition, the company has developed and launched a wide range of generic and branded injectables, including Cefazolin, Cefuroxime, and Amikacin.
Share Price: ₹1772.30 per share as on 20 Dec, 2024 04:01 PM
Market Capitalisation: ₹29,060.56Cr as of today
Revenue: ₹1,405.83Cr as on September 2024 (Q3 24)
Net Profit: ₹163.53Cr as on September 2024 (Q3 24)
Listing date: 20 Nov, 2020
Chairperson Name: Yiu Kwan Stanley Lau
| Organisation | Gland Pharma Ltd |
| Headquarters | |
| Industry | Pharmaceuticals |
| E-voting on shares | Click here to vote |
Key events for Gland Pharma Ltd
Gland Pharma Receives FDA Approval Amid Mixed Ratings - 13 Dec, 2024
Gland Pharma's FDA approval for a new injectable product is overshadowed by analysts' 'Sell' ratings. A fund has also acquired a minor stake in the company.Gland Pharma Gains on USFDA Approval for Injectable Drug - 12 Dec, 2024
Gland Pharma received USFDA approval for Phytonadione Injectable Emulsion, leading to a significant rise in stock price. Despite a decline in net profit, the company anticipates strong sales from the new product, which is expected to launch soon through marketing partners.Gland Pharma Secures USFDA Approval for Injectable Emulsion - 11 Dec, 2024
Gland Pharma Ltd has received USFDA approval for its phytonadione injectable emulsion, used to treat coagulation disorders due to vitamin K deficiency. The product is expected to generate significant sales, with US sales of approximately $15 million reported for the past year.Gland Pharma Shows Signs of Recovery Potential - 09 Dec, 2024
Gland Pharma has recently bounced back after a 17% decline, testing the 100-week EMA. Experts suggest waiting for a breakout above Rs 1,892 for potential gains towards Rs 2,200.Gland Pharma Secures USFDA Approval for Glaucoma Treatment - 03 Dec, 2024
Gland Pharma Limited has received USFDA approval for its Latanoprost Ophthalmic Solution, a treatment for high intraocular pressure in glaucoma patients. The product, expected to launch in FY25, had US sales of approximately $111.6 million for the year ending December 2023.
Insights on Gland Pharma Ltd
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTRevenue Rich
Revenue is up for the last 2 quarters, 1.45K Cr → 1.46K Cr (in ₹), with an average increase of 0.8% per quarter
- POSITIVE IMPACT
MF Holding Up
Mutual Funds have increased holdings from 30.53% to 32.83% in Sep 2024 quarter
- POSITIVE IMPACT
Profit Spike
Netprofit is up for the last 2 quarters, 143.76 Cr → 163.53 Cr (in ₹), with an average increase of 12.1% per quarter
NO EFFECTPromoter Holding Unchanged
Promoters holdings remained unchanged at 51.83% of holdings in Sep 2024 quarter
- NO EFFECT
Against Peers
In the last 1 year, Divis Laboratories Ltd has given 57.1% return, outperforming this stock by 62.2%
- NO EFFECT
Against Peers
In the last 3 years, Sun Pharmaceuticals Industries Ltd has given 135.8% return, outperforming this stock by 187.3%
NEGATIVE IMPACTRetail Holding Down
Retail Investor have decreased holdings from 8.45% to 8.32% in Sep 2024 quarter
- NEGATIVE IMPACT
Price Dip
In the last 3 years, GLAND stock has moved down by -51.6%
- NEGATIVE IMPACT
FII Holding Down
Foreign Institutions have decreased holdings from 6.88% to 4.47% in Sep 2024 quarter
Gland Pharma Ltd Financials
Index Inclusions
Gland Pharma Ltd Shareholding Pattern
| Investors | Holdings % | FY Quarter | 3M change |
|---|---|---|---|
| Promoter Holdings | 51.83% | 0.00 | |
| Foreign Institutions | 4.47% | ||
| Mutual Funds | 32.83% | 7.53 | |
| Retail Investors | 8.32% | ||
| Others | 2.54% | 10.52 |
Gland Pharma Ltd Key Indicators
Gland Pharma Ltd Valuation
Gland Pharma Ltd in the last 5 years
Lowest (18.84x)
May 22, 2023
Today (42.33x)
December 19, 2024
Industry (56.23x)
December 19, 2024
Highest (67.14x)
August 12, 2021
Gland Pharma Ltd Earnings and Dividends
Gland Pharma Ltd Earnings Results
Gland Pharma Ltd’s net profit fell -15.74% since last year same period to ₹163.53Cr in the Q2 2024-2025. On a quarterly growth basis, Gland Pharma Ltd has generated 13.75% jump in its net profits since last 3-months.
Read More about Earnings ResultsGland Pharma Ltd Dividends May,2024
In the quarter ending March 2024, Gland Pharma Ltd has declared dividend of ₹20 - translating a dividend yield of 1.13%.
Read More about Dividends
Gland Pharma Ltd Technicals Summary
Bearish
Neutral
Bullish
Gland Pharma Ltd is currently in a Bearish trading position according to technical analysis indicators.
FAQs on Gland Pharma Ltd
- Get a PAN card.
- Open a Demat account.
- Open a Trading account.
- Link your Demat account to your Trading account.
- Fund your Trading account.
- Place an order to buy Gland Pharma Ltd shares.
Gland Pharma Ltd (GLAND) share price today is ₹1772.3
Gland Pharma Ltd is listed on NSE
Gland Pharma Ltd is listed on BSE
- Today’s highest price of Gland Pharma Ltd is ₹1794.8.
- Today’s lowest price of Gland Pharma Ltd is ₹1765.
PE Ratio of Gland Pharma Ltd is 42.33
PE ratio = Gland Pharma Ltd Market price per share / Gland Pharma Ltd Earnings per share
Today’s traded volume of Gland Pharma Ltd(GLAND) is 1.01L.
Today’s market capitalisation of Gland Pharma Ltd(GLAND) is ₹29060.56Cr.
| Gland Pharma Ltd(GLAND | Price |
|---|---|
52 Week High | ₹2220.95 |
52 Week Low | ₹1585.7 |
Gland Pharma Ltd(GLAND) share price is ₹1772.3. It is down -20.20% from its 52 Week High price of ₹2220.95
Gland Pharma Ltd(GLAND) share price is ₹1772.3. It is up 11.77% from its 52 Week Low price of ₹1585.7
| Gland Pharma Ltd(GLAND | Returns |
|---|---|
1 Day Returns | -5.3% |
1 Month Returns | -0.53% |
3 Month Returns | -3.72% |
1 Year Returns | -1.71% |